Aribio is set to make its international debut after securing a 10 trillion won licensing agreement for its Alzheimer's treatment, 'AR1001,' and establishing a global commercialization framework. The company aims to accelerate its goal of becoming a global enterprise with 1 trillion won in revenue by 2030 through this initiative.
According to Aribio, the company will jointly participate with Aribio Lab in the 'BIO USA (BIO International Convention 2026)' taking place in San Diego, California, from June 22.
During the event, the two companies plan to introduce 'AR1001,' along with follow-up pipelines for central nervous system (CNS) disorders, electronic drug technology, and vaccine and immune platform technologies while pursuing global partnerships.
Leveraging its experience from the global Phase 3 development of AR1001, Aribio will seek collaboration opportunities in subsequent CNS pipelines and electronic drug fields. The follow-up candidate AR1005 is currently under development as a treatment for dementia with Lewy bodies (DLB) and is undergoing Phase 2 clinical trials at Severance Hospital.
The electronic drug GVD-01, based on transcutaneous vibrational acoustic stimulation (tVAS), has completed exploratory clinical trials in early Alzheimer's patients and is expanding its indications to include mild cognitive impairment (MCI), post-stroke neuropsychiatric symptoms, and sleep disorders.
Aribio Lab is advancing its vaccine and immune platform commercialization based on the immune enhancer platform 'Lipo-pam™.' Currently, a Phase 2 clinical trial for a shingles vaccine is underway, and discussions regarding potential co-development and licensing collaborations based on Lipo-pam will take place at BIO USA.
An Aribio representative stated, "We plan to pursue partnerships in the CNS new drug, electronic drug, and vaccine and immune platform sectors at BIO USA."
Earlier, on May 14, Aribio announced it had signed an exclusive sales agreement with China's Puxing Pharmaceutical for the global development, approval, production, and commercialization of the oral Alzheimer's treatment candidate 'AR1001.' Within about ten days of this agreement, Aribio received $10 million (approximately 15 billion won) of a $600 million (approximately 7.1 trillion won) upfront payment related to the global exclusive sales contract for AR1001.
Through this agreement, Aribio has achieved cumulative technology transfer contract results amounting to 10 trillion won with AR1001. Previously, the company had signed licensing agreements totaling 3 trillion won with Samjin Pharmaceutical, Arsera, and Newcopama-Puxing Pharmaceutical.
Aribio plans to commence full-scale commercialization starting with the announcement of the top-line results from the global Phase 3 trial of AR1001, expected in September.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.